FIELD: medicine.
SUBSTANCE: group of inventions relates to methods of treating cancer comprising administering the synergistic combination of RM01183 or its pharmaceutically acceptable salt with a therapeutically effective amount of antimetabolite, wherein antimetabolite is selected from 5-fluorouracil, gemcitabine, cytarabine, capecitabine, decitabine, floxuridine, aminopterin, methotrexate, pemetrexed and raltitrexed, as well as to the use of said synergistic combinations for treating cancer and preparing a drug for treating cancer.
EFFECT: group of inventions is effective in treating cancer.
8 cl, 296 dwg, 26 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| ANTITUMOR THERAPEUTIC PREPARATIONS INCLUDING THE COMBINATION OF CARTILAGINOUS EXTRACT AND THAT OF ANTINEOPLASTIC AGENT PROVIDING HIGH EFFICIENCY AT LOW TOXIC SIDE EFFECTS | 1998 |
|
RU2195946C2 |
| CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2675270C2 |
| CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2014 |
|
RU2823603C2 |
